Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia


1Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
2Department of Cardiology, Zhengzhou University People’s Hospital, Zhengzhou, China
3Department of Cardiology, Henan Provincial People’s Hospital, Zhengzhou, China
4Department of Ultrasound, Henan Provincial People’s Hospital, Zhengzhou, China

Corresponding author: L. Li
E-mail: LiLidoccn@126.com

Received June 10, 2013
Accepted January 13, 2014
Published April 3, 2014
DOI http://dx.doi.org/10.4238/2014.April.3.10

ABSTRACT. The aim of this study was to observe the effects of atorvastatin combined with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. A total of 84 elderly hypercholesterolemic patients complicated with carotid atherosclerosis were divided into control group (atorvastatin alone) and combined group (atorvastatin combined with ezetimibe) and treated for 12 months. Carotid atherosclerosis-related indicators including blood lipid and high-sensitivity C-reactive protein (hsCRP) were determined before and after treatment. The levels of carotid intima-media thickness (CIMT), serum low density lipoprotein cholesterol (LDL-C) and hsCRP were markedly decreased (P < 0.05) after treatment in the
two groups, while the reduction of the levels of CIMT, serum LDL-C and hsCRP was more significant in the combined group ($P < 0.01$). After treatment, the levels of CIMT, serum LDL-C and hsCRP were distinctly different between combined and control group ($P < 0.05$). The combination of atorvastatin with ezetimibe could further decrease LDL-C and hsCRP levels and have certain effects on the progression of carotid atherosclerosis in elderly patients with hypercholesterolemia.

**Key words:** Ezetimibe; Atorvastatin; Carotid atherosclerosis; Hypercholesterolemia

**INTRODUCTION**

A reduction in low density lipoprotein cholesterol (LDL-C) by at least 30 to 50% can clinically benefit patients at high risk of coronary heart disease (CHD) and related diseases (Benge et al., 2012), but it is difficult to achieve this with atorvastatin alone. Recent clinical research has shown that atorvastatin in combination with cholesterol absorption inhibitor ezetimibe significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin alone (Roeters van Lennep et al., 2008), but whether the distinct decrease in LDL-C level by the combination of atorvastatin and ezetimibe can slow down or reverse the process of atherosclerosis is still inconclusive. In our research, we explored whether a more substantial reduction in LDL-C level could further ameliorate carotid atherosclerosis through comparing the effects of atorvastatin in combination with ezetimibe and atorvastatin alone on LDL-C, high-sensitivity C-reactive protein (hsCRP) and carotid intima-media thickness (CIMT).

**MATERIAL AND METHODS**

**Subjects**

A total of 84 elderly hypercholesterolemic patients, including 44 males and 40 females with an average age of (67.23 ± 5.64) years were selected in our department between July 2010 and December 2011. Among these patients, 70 of them were confirmed with CHD by coronary arteriography, 28 patients were diagnosed with type 2 diabetes according to criteria for the diagnosis and classification of diabetes published by WHO in 1999, and 10 cases were diabetes complicated with CHD. The patients with hypertension, blood diseases, hepato renal dysfunction, severe infectious disease and heart failure were excluded. All the selected patients who still had abnormal LDL-C levels (≤2.6 mM) after undergoing lipid-lowering therapy for three months were randomized into control and combined groups. No differences in age, gender, body mass index, blood pressure, and smoking were observed in patients between the two groups (Table 1).

**Methods**

The control and combined groups used atorvastatin alone (Lipitor, 20 mg/night,
Effects of atorvastatin in combination with ezetimibe

Pfizer, Inc.) and atorvastatin in combination with ezetimibe (Zetia, 10 mg/day, Merck Sharp & Dohme) for 12 months, respectively. Hepatorenal function, myocardial enzyme and glycosylated hemoglobin were monitored during drug application. Glycosylated hemoglobin level in patients with diabetes was controlled within 7%. CIMT, carotid plaque Crouse integral, carotid diameter, blood lipid level and hsCRP were detected before and after treatment. CIMT measurement: CIMT was detected three times 10 mm away from the bifurcation of bilateral common carotid artery and average was calculated; 0.9 mm ≤ IMT < 1.3 mm was defined as thickening and IMT ≥ 1.3 mm refers to plaque. Carotid plaque Crouse integral measurement: maximum thickness (mm) of the isolated plaques in bilateral carotid artery was added regardless of length of various plaques. Blood lipid level and hsCRP were determined with a Hitachi 7060 automatic biochemistry analyzer and glycosylated hemoglobin was determined by affinity chromatography.

### Table 1. General data of patients in two groups (means ± SD).

<table>
<thead>
<tr>
<th>Items</th>
<th>Control group (N = 44)</th>
<th>Combined group (N = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male/female, cases)</td>
<td>22/22</td>
<td>22/18</td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.31 ± 5.82</td>
<td>67.21 ± 6.40</td>
</tr>
<tr>
<td>Body mass index</td>
<td>24.72 ± 4.42</td>
<td>24.43 ± 4.61</td>
</tr>
<tr>
<td>Etiological factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD (cases)</td>
<td>34</td>
<td>36</td>
</tr>
<tr>
<td>Diabetes (cases)</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Systolic pressure (mmHg)</td>
<td>132.52 ± 15.43</td>
<td>133.52 ± 15.24</td>
</tr>
<tr>
<td>Diastolic pressure (mmHg)</td>
<td>66.31 ± 10.52</td>
<td>65.45 ± 9.62</td>
</tr>
</tbody>
</table>

1 mmHg = 0.133 kPa; CHD = coronary heart disease.

### Statistical analysis

Data were analyzed with SPSS12.0 software and measurement data are reported as means ± SD. Comparison before and after treatment within groups was done with a t-test and comparison between groups by variance analysis. P < 0.05 was considered to be statistically significant.

### RESULTS

**Comparison of blood lipid and hsCRP before and after treatment between two groups**

The levels of serum LDL-C, triglycerides and hsCRP in the two groups distinctly declined after 12-months treatment compared with levels before treatment, while the serum high density lipoprotein cholesterol (HDL-C) level markedly increased (P < 0.05, Table 2). The reduction in the levels of CIMT, serum LDL-C and hsCRP was more significant in the combined group (P < 0.01, Table 2). After treatment, the levels of serum LDL-C and hsCRP were significantly lower in the combined group than those in the control group (P < 0.05, Table 2). Serum HDL-C increased and triglycerides decreased after 12-months treatment in the combined group compared with the control group, but these changes were not statistically significant.
Comparison of CIMT, carotid plaque Crouse integral and carotid inner diameter before and after treatment between two groups

No differences in various indicators were observed before treatment in the two groups. CIMT and carotid plaque Crouse integral dramatically decreased, and carotid inner diameter increased notably after 12-months treatment compared with that before treatment in both the control (P < 0.05, Table 3) and combined (P < 0.01, Table 3) groups, where the reduction in CIMT and carotid plaque Crouse integral was more significant in the combined group. After treatment, the levels of CIMT and carotid plaque Crouse integral were significantly lower in the control group than in the control group. The change in CIMT before and after treatment in the two groups is shown in Figures 1-4: Figure 1 represents the control group before treatment, where CIMT was 1.2 mm; Figure 2 represents the control group after one year of treatment, where CIMT decreased to 1.1 mm; Figure 3 represents the combined group before treatment, where CIMT was 1.4 mm; Figure 4 represents the combined group after one year of treatment, where CIMT was 1.2 mm.

<table>
<thead>
<tr>
<th>Table 2. Comparison of blood lipid and hs-CRP before and after treatment between two groups (means ± SD).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group (N = 44)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>TC (mM)</td>
</tr>
<tr>
<td>LDL-C (mM)</td>
</tr>
<tr>
<td>HDL-C (mM)</td>
</tr>
<tr>
<td>TG (mM)</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
</tr>
</tbody>
</table>

Compared with that before treatment,*P < 0.05, **P < 0.01; compared with control group after treatment, ΔP < 0.05.

TC = total cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; TG = triglyceride; hsCRP = high-sensitivity C-reactive protein.

Comparison of cardiovascular events and safety

There were no events of myocardial infarction and cardiovascular death during a 12-month follow-up. One patient in the control group had a transient elevation in glutamic-pyruvic transaminase and glutamic oxalacetic transaminase levels, but they were lower than three times the upper limit of normal, which recovered back to the normal range after application of atorvastatin; creatine kinase was not unusually high; there were no myalgia, rashes or other clinical adverse reactions.
Effects of atorvastatin in combination with ezetimibe

Figure 1. Before treatment in control group.

Figure 2. After treatment in control group.

Figure 3. Before treatment in combined group.
DISCUSSION

Intensive lipid-lowering is an important measure for primary and secondary prevention of cardiovascular disease. It is more important for patients at high risk or very high risk of cardiovascular event to receive statin treatment to reduce LDL-C levels back to normal or by 30 to 50%. However, the initial dose of the statins can reduce LDL-C level by 20 to 30%, and doubling the dose only provides a 5 to 6% further decrease (Wierzbicki and Mikhailidis, 2002). On the other side, it is very dangerous to increase the statin dose without paying attention to drug safety. Ezetimibe is a novel cholesterol-lowering drug, which decreases lipid levels by selectively inhibiting the absorption of cholesterol by brush border of jejunum mucosa (Clearfield, 2003). The combination of statin and ezetimibe stops both the synthesis and absorption of cholesterol so as to synergistically reduce LDL-C. Many clinical trials have demonstrated that statin combined with ezetimibe significantly reduces the levels of LDL-C and hsCRP, which is superior to statin alone in lipid-lowering efficacy (Stein et al., 2004; Ballantyne et al., 2007; Okada et al., 2012). A recent study has confirmed that ezetimibe not only decreases cholesterol absorption but also affects the process of atherosclerosis by inhibiting Rho kinase activity (Nochioka et al., 2012). Thus, the combination is able to reduce major atherosclerotic events and all-cause mortality (Hayek et al., 2013).

Atherosclerosis is the most common and important pathologic change in cardiovascular disease that causes disability and death. The increase in CIMT is a noninvasive indicator to evaluate early stages of atherosclerosis, as well as an important hazard and predictive factor of cardiovascular disease (Robertson et al., 2012). Extensive research has confirmed that the incidence of cardiovascular events increases when CIMT is elevated in type 2 diabetic patients (Irie et al., 2012). Keo et al. (2011) found that CIMT closely correlates with ischemic events in patients with atherosclerotic vascular disease. Evidence-based medicine has shown that lipid-lowering to normal levels is always accompanied by the vanishing, delayed development or stopping of atherosclerotic plaque. When comparing atorvastatin and simvastatin for their effect on the development of atherosclerosis in the ASAP study, it was discovered that a large
dose of atorvastatin could reduce LDL-C level as well as CIMT level (Smilde et al., 2001). Data analysis from the SANDS study revealed that the application of simvastatin or simvastatin plus ezetimibe could reduce the LDL-C level in type 2 diabetic patients over 40 years old, and there was a positive correlation between the improvement degree of carotid artery atherosclerosis and the extent of LDL-C reduction (Fleg et al., 2008). hsCRP is an important proinflammatory factor that is closely related to atherosclerosis occurrence and development. A to Z research and PROVE IT trials showed that the patients with a low level of hsCRP had a better prognosis and that the fatality rate of patients with high level of hsCRP rose exponentially (Morrow et al., 2006; Scirica et al., 2009). Some research has revealed that hsCRP is independently associated with cardiovascular events in the patients with arteriosclerosis and arterial occlusive disease (Kablak-Ziembicka et al., 2011). Numerous studies have confirmed that hsCRP level markedly declines and that vascular endothelial function apparently improves along with the decrease in LDL-C (Heart Protection Study Collaborative Group et al., 2011; Grigore et al., 2013).

Our research revealed that the levels of serum LDL-C, triglyceride and hsCRP in patients were markedly decreased, CIMT and carotid plaque Crouse integral clearly ameliorated, and the coronary inner diameter distinctly increased after atorvastatin treatment or atorvastatin in combination with ezetimibe, while the reduction in serum LDL-C and hsCRP was more significant and the decrease in CIMT and carotid plaque Crouse integral was greater in the combined group. After treatment, serum LDL-C and hsCRP levels, as well as CIMT and carotid plaque Crouse integral were statistically lower in the combined group versus control group. These results indicated that the combination of atorvastatin with ezetimibe had stronger hypolipidemic and anti-inflammatory effects, simultaneously further improved CIMT and carotid plaque Crouse integral, and slowed down the progression of carotid atherosclerosis in elderly patients with hypercholesterolemia. In addition, the hsCRP level in patients was slightly high in our study, which was considered to correlate with CHD, arteriosclerosis, diabetes, hypercholesterolemia, etc.

However, whether the distinct decrease in serum LDL-C level by the combination of atorvastatin with ezetimibe can slow down or reverse the process of atherosclerosis is still controversial. The ENHANCE group randomized 720 patients with heterozygous hypercholesterolemia into an atorvastatin in combination with ezetimibe group and atorvastatin group, but there was no significant difference in CIMT change between two groups after two-years of treatment (Kastelein et al., 2008). Most authors believe that the ENHANCE study did not set the CIMT baseline, which led to the negative result; this research can not affect current clinical intensive lipid-lowering strategy (Gandhi, 2008), and large studies on atorvastatin in combination with ezetimibe are being conducted with clinical endpoint events for this purpose. The long-term efficacy of ezetimibe requires further investigation.

In conclusion, the combination of atorvastatin with ezetimibe could further decrease serum LDL-C and hsCRP levels so as to ameliorate CIMT. However, whether intensive lipid-lowering can slow down or reverse the process of atherosclerosis is still controversial, which requires scientific large-scale clinical trials to confirm this.

REFERENCES


